Mizuho Maintains Outperform on Harmony Biosciences, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains an Outperform rating on Harmony Biosciences and raises the price target from $42 to $52.
October 10, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh has reaffirmed an Outperform rating for Harmony Biosciences and increased the price target from $42 to $52, indicating a positive outlook.
The increase in price target from $42 to $52 by Mizuho suggests a positive outlook for Harmony Biosciences, likely leading to a short-term increase in stock price. The Outperform rating further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100